Collaboration and License Agreements (Details)	1 Months Ended			3 Months Ended		6 Months Ended		12 Months Ended			15 Months Ended	33 Months Ended
	Feb. 28, 2015 USD ($)	Oct. 31, 2014 USD ($)	Jul. 31, 2006 USD ($) $ / shares shares	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($) item	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Dec. 31, 2013 USD ($)	Sep. 30, 2011	Mar. 31, 2015
Collaboration revenues:
Product revenue				$ 19,305,000	$ 5,690,000	$ 22,027,000	$ 10,502,000
Research and development revenue
Regulatory and commercial milestones				20,000,000		20,000,000
Amortization of upfront payments				2,442,000	860,000	4,130,000	1,901,000
Research and development services and external costs				3,153,000	4,400,000	7,306,000	9,332,000
Total research and development revenue				25,595,000	5,260,000	31,436,000	11,233,000
Total collaboration revenue				44,900,000	10,950,000	53,463,000	21,735,000
Operating expenses:
Research and Development Expense				976,000	3,708,000	1,762,000	8,841,000
General and Administrative Expense				372,000	300,000	965,000	483,000
Total Operating expenses				1,348,000	4,008,000	2,727,000	9,324,000
2003 Sandoz Collaboration
Collaboration revenues:
Product revenue				121,000	5,690,000	2,843,000	10,502,000
Research and development revenue
Research and development services and external costs				130,000	278,000	381,000	602,000
Total research and development revenue				130,000	278,000	381,000	602,000
Total collaboration revenue				251,000	5,968,000	3,224,000	11,104,000
Operating expenses:
Research and Development Expense				177,000	64,000	208,000	83,000
General and Administrative Expense				112,000	86,000	222,000	95,000
Total Operating expenses				289,000	150,000	$ 430,000	178,000
Percentage of contractual profits earned under collaborative arrangement											45.00%
Percentage of royalty for net sales up to pre-defined sales threshold												10.00%
Percentage of royalty for net sales above pre-defined sales threshold												12.00%
Percentage of royalty based on contractually defined profits on sales						50.00%
Profits recorded on sales				100,000
Claw-back adjustment of pre-launch development expenses				100,000
Maximum percentage of reduction of profit-share, royalty and milestone payments from Sandoz at each quarter						50.00%
Reduction in product revenue due to netting of shared development and other expenses								$ 1,900,000	$ 2,200,000
Collaborative Arrangement, carry forward to future periods						$ 1,800,000
Decrease in amount of adjustment related to product revenue						$ 2,100,000
Number of significant deliverables identified in arrangement | item						2
Second Sandoz Collaboration Agreement
Collaboration revenues:
Product revenue				19,184,000		$ 19,184,000
Research and development revenue
Regulatory and commercial milestones				20,000,000		20,000,000
Amortization of upfront payments					120,000		359,000
Research and development services and external costs				794,000	604,000	1,478,000	794,000
Total research and development revenue				20,794,000	724,000	21,478,000	1,153,000
Total collaboration revenue				39,978,000	724,000	40,662,000	1,153,000
Operating expenses:
Research and Development Expense				282,000	232,000	429,000	529,000
General and Administrative Expense				33,000	88,000	110,000	231,000
Total Operating expenses				315,000	320,000	$ 539,000	760,000
Percentage of royalty based on contractually defined profits on sales						50.00%
Profits recorded on sales				28,200,000
Number of shares sold | shares			4,708,679
Per share price of shares sold | $ / shares			$ 15.93
Closing price of the company's common stock on the NASDAQ Global Market (in dollars per share) | $ / shares			$ 13.05
Aggregate purchase price of shares sold			$ 75,000,000
Premium paid			$ 13,600,000
Collaborative Arrangement, Legal Expenses				9,000,000
Second Sandoz Collaboration Agreement | Maximum
Operating expenses:
Milestone payments possible per agreement				143,000,000		$ 143,000,000		143,000,000
Commercial milestone payments				10,000,000		10,000,000		10,000,000
Sales-based and commercial milestone payments possible per agreement				120,000,000		120,000,000		120,000,000
Sales-based and commercial milestone payments possible in European Union						$ 23,000,000
Regulatory milestone payment earned				10,000,000
Second Sandoz Collaboration Agreement | Novartis Pharma AG
Operating expenses:
Percentage of contractual profits earned under collaborative arrangement						50.00%
Baxalta Agreement
Research and development revenue
Amortization of upfront payments				2,442,000	740,000	$ 4,130,000	1,542,000
Research and development services and external costs				2,229,000	3,518,000	5,447,000	7,936,000
Total research and development revenue				4,671,000	4,258,000	9,577,000	9,478,000
Total collaboration revenue				4,671,000	4,258,000	9,577,000	9,478,000
Operating expenses:
Research and Development Expense				517,000	3,412,000	1,125,000	8,229,000
General and Administrative Expense				227,000	126,000	633,000	157,000
Total Operating expenses				744,000	$ 3,538,000	$ 1,758,000	$ 8,386,000
Number of independent companies completed restructuring activities | item						2
Number of additional biosimilars under the agreement | item						4
Upfront payment paid by Baxter to the company						$ 33,000,000
Option payments agreed to be paid by Baxter with respect to additional product candidates						12,000,000
Option payment which the entity is no longer eligible to receive						7,000,000
Remaining payment obligation				$ 0		$ 0		$ 0
Baxalta Agreement | Accounting Standards Update 2009 to 2013 Member
Operating expenses:
Number of significant deliverables identified in arrangement | item						7
Current number of significant deliverables identified in arrangement | item						6
Total arrangement consideration						$ 61,000,000
Portion of arrangement consideration allocated to the first initial product license						10,300,000
Portion of arrangement consideration allocated to each of the four additional product licenses						10,300,000
Portion of arrangement consideration allocated to the second initial product license						9,400,000
Portion of arrangement consideration allocated to the joint steering committee unit of accounting						$ 114,000
Reduction in total arrangement consideration		$ 7,000,000								$ 7,000,000
Reduction in number of significant deliverables identified in arrangement | item						1
Portion of revised arrangement consideration reallocated to the remaining deliverables	$ 40,000,000	61,000,000								54,000,000
Portion of revised arrangement consideration allocated to the first initial product license as a result of termination of product	39,600,000	12,400,000								11,000,000
Portion of revised arrangement consideration allocated to each of the three additional product licenses as a result of termination of product	$ 400,000	12,400,000								11,000,000
Portion of revised arrangement consideration allocated to the second initial product license as a result of termination of product		11,300,000								10,000,000
Portion of revised arrangement consideration allocated to the joint steering committee unit of accounting as a result of termination of product		$ 137,000								$ 122,000
Decrease in portion of revised arrangement consideration reallocated to the remaining deliverables						$ 40,000,000
Number of follow-on biologic products for development and product licenses | item						2
Number of additional follow-on biologic products for development and product licenses | item						4
Number of follow-on biologic products for research and development services | item						2
Number of additional follow-on biologic products for research and development services | item						4
Number of vendors selling similar, competing products on a stand-alone basis | item						0
Number of license agreements | item						6
Deferred revenue						$ 26,900,000
Deferred revenue included in current liabilities						9,800,000
Deferred revenue included in non-current liabilities						17,100,000
Baxalta Agreement | Maximum
Operating expenses:
Aggregate regulatory milestone to be paid by Baxter						$ (50,000,000)